

Supplementary Information

Figure S1. Results of high-resolution melting (HRM) analysis of the g.46438521G>C polymorphism (rs4462560) of the *NEIL1* gene. Homozygous G/G and C/G, and heterozygous C/C samples are shown on standard normalized melt curves and difference curves. Arrows indicate the different genotypes.




Figure S2. Results of the TaqMan[®] SNP Genotyping Assay of the c.2285T>C polymorphism (rs1136410) of the *PARP-1* gene. The X-axis represents the relative fluorescent emission for the T allele-specific probe labeled with 6-carboxyfluorescein (FAM), and the Y-axis represents the emission for the C allele-specific probe labeled with 2'-chloro-7'-phenyl-1,4-dichloro-6-carboxyfluorescein (VIC). Circles—homozygous GG; triangles—heterozygous AG. Diamonds represent no template controls.




Figure S3. Results of the restriction fragments length polymorphism analysis of the c.-1370T>A polymorphism (rs1054875) of the *POLG* gene on an 8% polyacrylamide gel. Lane M shows a M100-500 DNA marker ladder, with length of the fragment indicated left to the picture. Genotypes are shown above the picture.




Figure S4. Results of the restriction fragments length polymorphism analysis of the c.580C>T polymorphism (rs1799782) of the *XRCC1* gene on an 8% polyacrylamide gel. Lane M shows a GeneRuler™ 100 bp marker ladder, with length of the fragment indicated left to the picture. Genotypes are shown above the picture.




Figure S5. Results of the restriction fragments length polymorphism analysis of the c.1196A>G polymorphism (rs25487) of the *XRCC1* gene on an 8% polyacrylamide gel. Lane M shows a M100-500 DNA marker ladder, with length of the fragment indicated left to the picture. Genotypes are shown above the picture.




Table S1. Distribution of combined genotypes of the g.46438521G>C—*NEIL1* and c.2285T>C—*PARP-1* polymorphisms and odds ratio (OR) with 95% confidence interval (95% CI) in patients with keratoconus (KC) and controls.

Combined Genotypes	Controls (<i>n</i> = 353)		KC (<i>n</i> = 284)		Crude OR (95% CI)	<i>P</i>	Adjusted OR ^a (95% CI)	<i>P</i>
	Number	Frequency	Number	Frequency				
C/C–A/A	64	0.18	48	0.17	0.92 (0.61–1.37)	0.686	0.48 (0.25–0.89)	0.019
C/C–A/G	34	0.10	29	0.10	1.67 (0.63–1.80)	0.808	1.19 (0.57–2.50)	0.643
C/C–G/G	0	0.00	0	0.00	–	–	–	–
C/G–A/A	167	0.47	132	0.46	0.97 (0.71–1.32)	0.835	1.35 (0.86–2.12)	0.193
C/G–A/G	73	0.21	56	0.20	0.94 (0.63–1.39)	0.764	0.95 (0.54–1.65)	0.850
C/G–G/G	0	0.00	0	0.00	–	–	–	–
G/G–A/A	8	0.02	11	0.04	1.74 (0.69–4.38)	0.241	1.57 (0.37–6.64)	0.541
G/G–A/G	7	0.02	8	0.03	1.43 (0.51–4.00)	0.492	1.24 (0.26–5.88)	0.786
G/G–G/G	0	0.00	0	0.00	–	–	–	–

p values <0.05 along with corresponding ORs are in bold; ^a OR adjusted for sex, age, co-occurrence of visual impairment, allergies, and family history for KC.

Table S2. Distribution of combined genotypes of the g.46438521G>C—*NEIL1* and c.–1370T>A—*POLG* polymorphisms and odds ratio (OR) with 95% confidence interval (95% CI) in patients with keratoconus (KC) and controls.

Combined Genotypes	Controls (<i>n</i> = 353)		KC (<i>n</i> = 284)		Crude OR (95% CI)	<i>P</i>	Adjusted OR ^a (95% CI)	<i>P</i>
	Number	Frequency	Number	Frequency				
C/C–A/A	14	0.04	17	0.06	1.52 (0.75–3.18)	0.242	1.56 (0.52–4.69)	0.424
C/C–A/T	30	0.08	42	0.15	1.89 (1.14–3.07)	0.014	3.73 (1.76–7.87)	<0.001
C/C–T/T	2	0.01	3	0.01	1.87 (0.31–11.29)	0.493	0.29 (0.03–2.55)	0.267
C/G–A/A	57	0.16	40	0.14	0.85 (0.54–1.32)	0.472	0.45 (0.24–0.84)	0.012
C/G–A/T	140	0.40	91	0.32	0.72 (0.51–0.99)	0.047	0.66 (0.41–1.05)	0.083
C/G–T/T	6	0.02	8	0.03	1.68 (0.57–4.89)	0.344	2.48 (0.45–13.58)	0.295
G/G–A/A	27	0.08	20	0.07	0.91 (0.50–1.67)	0.771	1.04 (0.42–2.58)	0.933
G/G–A/T	70	0.20	55	0.19	0.97 (0.65–1.44)	0.884	1.23 (0.70–2.16)	0.472

Table S2. Cont.

Combined Genotypes	Controls (<i>n</i> = 353)		KC (<i>n</i> = 284)		Crude OR (95% CI)	<i>p</i>	Adjusted OR ^a (95% CI)	<i>p</i>
	Number	Frequency	Number	Frequency				
G/G–T/T	7	0.02	8	0.03	1.43 (0.51–4.00)	0.492	1.83 (0.36–9.16)	0.463

p values <0.05 along with corresponding ORs are in bold; ^a OR adjusted for sex, age, co-occurrence of visual impairment, allergies, and family history for KC.

Table S3. Distribution of combined genotypes of the g.46438521G>C—*NEILI* and c.580C>T—*XRCCI* polymorphisms and odds ratio (OR) with 95% confidence interval (95% CI) in patients with keratoconus (KC) and controls.

Combined Genotypes	Controls (<i>n</i> = 353)		KC (<i>n</i> = 284)		Crude OR (95% CI)	<i>p</i>	Adjusted OR ^a (95% CI)	<i>p</i>
	Number	Frequency	Number	Frequency				
C/C–C/C	82	0.23	68	0.24	1.04 (0.72–1.50)	0.833	0.71 (0.41–1.22)	0.213
C/C–C/T	16	0.05	9	0.03	0.69 (0.30–1.58)	0.381	0.52 (0.16–1.74)	0.290
C/C–T/T	0	0.00	0	0.00	–	–	–	–
C/G–C/C	210	0.59	175	0.62	1.09 (0.79–1.50)	0.585	1.52 (0.95–2.44)	0.080
C/G–C/T	30	0.08	13	0.05	0.52 (0.26–1.01)	0.053	0.58 (0.23–1.49)	0.262
C/G–T/T	0	0.00	0	0.00	–	–	–	–
G/G–C/C	13	0.04	19	0.07	1.87 (0.91–3.87)	0.089	0.36 (0.23–0.58)	0.253
G/G–C/T	2	0.01	0	0.00	–	–	–	–
G/G–T/T	0	0.00	0	0.00	–	–	–	–

^a OR adjusted for sex, age, co-occurrence of visual impairment, allergies, and family history for KC.

Table S4. Distribution of combined genotypes of the g.46438521G>C—*NEILI* and c.1196A>G—*XRCCI* polymorphisms and odds ratio (OR) with 95% confidence interval (95% CI) in patients with keratoconus (KC) and controls.

Combined Genotypes	Controls (<i>n</i> = 353)		KC (<i>n</i> = 284)		Crude OR (95% CI)	<i>p</i>	Adjusted OR ^a (95% CI)	<i>p</i>
	Number	Frequency	Number	Frequency				
C/C–A/A	24	0.07	19	0.07	0.94 (0.49–1.80)	0.846	1.56 (0.59–4.10)	0.371
C/C–A/G	59	0.17	54	0.19	0.65 (0.41–1.05)	0.081	0.92 (0.91–0.94)	0.029
C/C–G/G	15	0.04	4	0.01	0.74 (0.31–1.78)	0.509	0.57 (0.19–1.70)	0.318
C/G–A/A	48	0.14	40	0.14	1.79 (1.17–2.75)	0.007	2.17 (1.52–4.09)	0.017

Table S4. Cont.

Combined Genotypes	Controls (<i>n</i> = 353)		KC (<i>n</i> = 284)		Crude OR (95% CI)	<i>p</i>	Adjusted OR ^a (95% CI)	<i>p</i>
	Number	Frequency	Number	Frequency				
C/G–A/G	146	0.41	136	0.48	1.08 (0.78–1.50)	0.652	1.29 (0.80–2.08)	0.297
C/G–G/G	46	0.13	12	0.04	0.74 (0.44–1.24)	0.256	0.42 (0.20–0.84)	0.015
G/G–A/A	0	0.00	4	0.01	–	–	–	–
G/G–A/G	13	0.04	13	0.05	0.64 (0.24–1.72)	0.378	1.39 (0.39–4.95)	0.615
G/G–G/G	2	0.01	2	0.01	–	–	–	–

p values <0.05 along with corresponding ORs are in bold; ^a OR adjusted for sex, age, co-occurrence of visual impairment, allergies, and family history for KC.

Table S5. Distribution of combined genotypes of the c.2285T>C—*PARP-1* and c.–1370T>A—*POLG* polymorphisms and odds ratio (OR) with 95% confidence interval (95% CI) in patients with keratoconus (KC) and controls.

Combined Genotypes	Controls (<i>n</i> = 353)		KC (<i>n</i> = 284)		Crude OR (95% CI)	<i>p</i>	Adjusted OR ^a (95% CI)	<i>p</i>
	Number	Frequency	Number	Frequency				
A/A–A/A	29	0.08	40	0.14	1.83 (1.10–3.04)	0.019	2.73 (1.29–5.78)	0.009
A/A–A/T	17	0.05	22	0.08	1.66 (0.86–3.19)	0.128	2.09 (0.79–5.52)	0.135
A/A–T/T	0	0.00	0	0.00	–	–	–	–
A/G–A/A	143	0.41	92	0.32	0.70 (0.51–0.98)	0.035	0.47 (0.29–0.76)	0.002
A/G–A/T	60	0.17	47	0.17	0.97 (0.64–1.47)	0.881	0.92 (0.91–0.94)	0.797
A/G–T/T	0	0.00	0	0.00	–	–	–	–
G/G–A/A	67	0.19	59	0.21	1.12 (0.76–1.65)	0.572	0.36 (0.22–0.57)	0.150
G/G–A/T	37	0.10	24	0.08	0.79 (0.46–1.35)	0.387	0.81 (0.37–1.75)	0.590
G/G–T/T	0	0.00	0	0.00	–	–	–	–

p values <0.05 along with corresponding ORs are in bold; ^a OR adjusted for sex, age, co-occurrence of visual impairment, allergies, and family history for KC.

Table S6. Distribution of combined genotypes of the c.2285T>C—*PARP-1* and c.580C>T—*XRCC1* polymorphisms and odds ratio (OR) with 95% confidence interval (95% CI) in patients with keratoconus (KC) and controls.

Combined Genotypes	Controls (<i>n</i> = 353)		KC (<i>n</i> = 284)		Crude OR (95% CI)	<i>p</i>	Adjusted OR ^a (95% CI)	<i>p</i>
	Number	Frequency	Number	Frequency				
A/A–C/C	204	0.58	175	0.62	1.17 (0.85–1.61)	0.328	1.16 (0.73–1.83)	0.524
A/A–C/T	35	0.10	16	0.06	0.54 (0.29–1.01)	0.051	0.49 (0.20–1.16)	0.106
A/A–T/T	0	0.00	0	0.00	–	–	–	–
A/G–C/C	101	0.29	87	0.31	1.10 (0.78–1.55)	0.578	1.15 (0.70–1.88)	0.576
A/G–C/T	13	0.04	6	0.02	0.56 (0.21–1.50)	0.253	0.52 (0.13–2.11)	0.362
A/G–T/T	0	0.00	0	0.00	–	–	–	–
G/G–C/C	0	0.00	0	0.00	–	–	–	–
G/G–C/T	0	0.00	0	0.00	–	–	–	–
G/G–T/T	0	0.00	0	0.00	–	–	–	–

^a OR adjusted for sex, age, co-occurrence of visual impairment, allergies, and family history for KC.

Table S7. Distribution of combined genotypes of the c.2285T>C—*PARP-1* and c.1196A>G—*XRCC1* polymorphisms and odds ratio (OR) with 95% confidence interval (95% CI) in patients with keratoconus (KC) and controls.

Combined Genotypes	Controls (<i>n</i> = 353)		KC (<i>n</i> = 284)		Crude OR (95% CI)	<i>p</i>	Adjusted OR ^a (95% CI)	<i>p</i>
	Number	Frequency	Number	Frequency				
A/A–A/A	52	0.15	45	0.16	1.37 (0.89–2.12)	0.147	2.62 (1.36–5.07)	0.004
A/A–A/G	144	0.41	136	0.48	0.92 (0.66–1.28)	0.623	1.10 (0.68–1.77)	0.699
A/A–G/G	43	0.12	10	0.04	0.66 (0.38–1.14)	0.140	0.38 (0.19–0.78)	0.008
A/G–A/A	20	0.06	18	0.06	1.93 (1.05–3.55)	0.033	1.46 (0.60–3.56)	0.407
A/G–A/G	74	0.21	67	0.24	0.85 (0.56–1.28)	0.438	0.77 (0.43–1.40)	0.398
A/G–G/G	20	0.06	8	0.03	0.84 (0.40–1.75)	0.641	0.54 (0.19–1.56)	0.259
G/G–A/A	0	0.00	0	0.00	–	–	–	–
G/G–A/G	0	0.00	0	0.00	–	–	–	–
G/G–G/G	0	0.00	0	0.00	–	–	–	–

p values <0.05 along with corresponding ORs are in bold; ^a OR adjusted for sex, age, co-occurrence of visual impairment, allergies, and family history for KC.

Table S8. Distribution of combined genotypes of the c.-1370T>A—*POLG* and c.580C>T—*XRCC1* polymorphisms and odds ratio (OR) with 95% confidence interval (95% CI) in patients with keratoconus (KC) and controls.

Combined Genotypes	Controls (<i>n</i> = 353)		KC (<i>n</i> = 284)		Crude OR (95% CI)	<i>p</i>	Adjusted OR ^a (95% CI)	<i>p</i>
	Number	Frequency	Number	Frequency				
A/A–C/C	41	0.12	60	0.21	2.04 (1.32–3.14)	0.001	3.05 (1.59–5.86)	<0.001
A/A–C/T	5	0.01	2	0.01	0.49 (0.09–2.56)	0.401	0.54 (0.06–4.58)	0.574
A/A–T/T	0	0.00	0	0.00	–	–	–	–
A/T–C/C	175	0.50	127	0.45	0.82 (0.60–1.13)	0.223	0.63 (0.40–0.99)	0.046
A/T–C/T	28	0.08	12	0.04	0.51 (0.26–1.03)	0.059	0.30 (0.12–0.79)	0.014
A/T–T/T	0	0.00	0	0.00	–	–	–	–
T/T–C/C	89	0.25	75	0.26	1.06 (0.74–1.52)	0.732	1.23 (0.73–2.07)	0.438
T/T–C/T	15	0.04	8	0.03	0.65 (0.27–1.56)	0.339	1.39 (0.37–5.04)	0.647
T/T–T/T	0	0.00	0	0.00	–	–	–	–

p values <0.05 along with corresponding ORs are in bold; ^a OR adjusted for sex, age, co-occurrence of visual impairment, allergies, and family history for KC.

Table S9. Distribution of combined genotypes of the c.-1370T>A—*POLG* and c.1196A>G—*XRCC1* polymorphisms and odds ratio (OR) with 95% confidence interval (95% CI) in patients with keratoconus (KC) and controls.

Combined Genotypes	Controls (<i>n</i> = 353)		KC (<i>n</i> = 284)		Crude OR (95% CI)	<i>p</i>	Adjusted OR ^a (95% CI)	<i>p</i>
	Number	Frequency	Number	Frequency				
A/A–A/A	6	0.02	13	0.05	2.77 (1.04–7.39)	0.041	2.73 (0.74–10.03)	0.131
A/A–A/G	31	0.09	46	0.16	2.01 (1.24–3.26)	0.005	3.01 (1.44–6.28)	0.003
A/A–G/G	9	0.03	3	0.01	0.41 (0.11–1.52)	0.182	0.66 (0.11–3.90)	0.652
A/T–A/A	41	0.12	33	0.12	1.00 (0.61–1.63)	0.998	1.34 (0.67–2.67)	0.414
A/T–A/G	118	0.33	100	0.35	1.08 (0.78–1.50)	0.637	0.92 (0.91–0.94)	0.926
A/T–G/G	44	0.12	6	0.02	0.15 (0.06–0.36)	< 0.001	0.04 (0.01–0.14)	<0.001
T/T–A/A	25	0.07	17	0.06	0.83 (0.44–1.58)	0.580	1.24 (0.50–3.08)	0.636
T/T–A/G	69	0.20	57	0.20	1.03 (0.70–1.53)	0.869	0.92 (0.91–0.94)	0.404

Table S9. Cont.

Combined Genotypes	Controls (<i>n</i> = 353)		KC (<i>n</i> = 284)		Crude OR (95% CI)	<i>p</i>	Adjusted OR ^a (95% CI)	<i>p</i>
	Number	Frequency	Number	Frequency				
T/T–G/G	10	0.03	9	0.03	1.12 (0.45–2.80)	0.804	0.87 (0.23–3.32)	0.846

p values <0.05 along with corresponding ORs are in bold; ^a OR adjusted for sex, age, co-occurrence of visual impairment, allergies, and family history for KC.

Table S10. Distribution of genotypes of the 46438521G>C—*NEIL1*, c.2285T>C—*PARP-1*, c.–1370T>A—*POLG*, c.580C>T—*XRCC1* and c.1196A>G—*XRCC1* polymorphisms stratified by sex in patients with keratoconus (KC) and controls.

Polymorphism	Controls		KC		Crude OR (95% CI)	<i>p</i>	Adjusted OR ^a (95% CI)	<i>p</i>
Genotype/Allele	Number	Frequency	Number	Frequency				
g.46438521G>C								
NEIL1								
women								
C/C	60	0.27	22	0.26	0.94 (0.53–1.66)	0.830	0.76 (0.36–0.49)	0.488
C/G	153	0.68	55	0.64	0.82 (0.49–1.39)	0.466	1.11 (0.55–2.27)	0.769
G/G	11	0.05	9	0.10	2.26 (0.90–5.67)	0.081	1.65 (0.42–6.55)	0.476
C	273	0.61	99	0.58	0.79 (0.49–1.26)	0.322	0.75 (0.40–1.41)	0.374
G	175	0.39	73	0.42	1.26 (0.79–2.02)	0.322	1.33 (0.71–2.47)	0.374
men								
C/C	38	0.29	55	0.28	0.92 (0.56–1.50)	0.742	0.53 (0.26–1.09)	0.089
C/G	87	0.67	133	0.67	0.99 (0.61–1.58)	0.959	1.80 (0.90–3.58)	0.095
G/G	4	0.03	10	0.05	1.66 (0.51–5.42)	0.399	0.99 (0.19–5.05)	0.988
C	163	0.63	243	0.61	0.87 (0.57–1.34)	0.536	0.61 (0.32–1.16)	0.131
G	95	0.37	153	0.39	1.14 (0.75–1.75)	0.536	1.63 (0.86–3.08)	0.131
c.2285T>C								
PARP-1								
women								
A/A	157	0.70	53	0.62	0.68 (0.41–1.15)	0.155	0.67 (0.34–1.34)	0.263
A/G	67	0.30	33	0.38	1.46 (0.87–2.45)	0.155	1.48 (0.74–2.96)	0.263
G/G	0	0.00	0	0.00	–	–	–	–

Table S10. *Cont.*

Polymorphism	Controls		KC		Crude OR (95% CI)	<i>P</i>	Adjusted OR ^a (95% CI)	<i>P</i>
Genotype/Allele	Number	Frequency	Number	Frequency				
c.2285T>C								
<i>PARP-1</i>								
women								
A	381	0.85	139	0.81	0.68 (0.41–1.15)	0.155	0.67 (0.34–1.34)	0.263
G	67	0.15	33	0.19	1.46 (0.87–2.45)	0.155	1.48 (0.74–2.96)	0.263
men								
A/A	82	0.64	138	0.70	1.28 (0.87–1.87)	0.289	1.01 (0.52–1.96)	0.973
A/G	47	0.36	60	0.30	0.77 (0.48–1.24)	0.289	0.99 (0.51–1.92)	0.973
G/G	0	0.00	0	0.00	–	–	–	–
A	211	0.82	336	0.85	1.29 (0.81–2.06)	0.289	1.01 (0.52–1.96)	0.973
G	47	0.18	60	0.15	0.77 (0.48–1.24)	0.289	0.99 (0.51–1.92)	0.973
c.–1370T>A								
<i>POLG</i>								
women								
A/A	30	0.13	21	0.24	2.09 (1.11–3.09)	0.021	3.22 (1.35–7.68)	0.008
A/T	125	0.56	37	0.43	0.60 (0.36–0.99)	0.045	0.35 (0.17–0.70)	0.003
T/T	69	0.31	28	0.33	1.08 (0.64–1.85)	0.766	1.45 (0.71–2.95)	0.298
A	185	0.41	79	0.46	1.22 (0.85–1.77)	0.280	1.21 (0.75–1.96)	0.438
T	263	0.59	93	0.54	0.82 (0.56–1.18)	0.280	0.83 (0.51–1.34)	0.438
men								
A/A	16	0.12	41	0.21	1.84 (0.99–3.45)	0.055	2.20 (0.90–5.38)	0.083
A/T	78	0.60	102	0.52	0.69 (0.44–1.09)	0.112	0.65 (0.34–1.22)	0.177
T/T	35	0.27	55	0.28	1.03 (0.63–1.70)	0.898	1.02 (0.50–2.07)	0.961
A	110	0.43	184	0.46	1.19 (0.85–1.67)	0.308	1.27 (0.78–2.07)	0.327
T	148	0.57	212	0.54	0.84 (0.60–1.17)	0.308	0.78 (0.48–1.27)	0.327

Table S10. *Cont.*

Polymorphism	Controls		KC		Crude OR		Adjusted OR ^a	
Genotype/Allele	Number	Frequency	Number	Frequency	(95% CI)	<i>P</i>	(95% CI)	<i>P</i>
c.580C>T								
<i>XRCCI</i>								
women								
C/C	198	0.88	78	0.91	1.28 (0.56–2.95)	0.562	1.23 (0.39–3.91)	0.723
C/T	26	0.12	8	0.09	0.78 (0.34–1.80)	0.562	0.81 (0.26–2.57)	0.723
T/T	0	0.00	0	0.00	–	–	–	–
C	418	0.93	164	0.95	1.51 (0.66–3.43)	0.328	2.92 (0.93–9.18)	0.066
T	30	0.07	8	0.05	0.66 (0.29–1.51)	0.328	0.34 (0.11–1.07)	0.066
men								
C/C	107	0.83	184	0.93	2.70 (1.33–5.50)	0.006	3.45 (1.25–9.49)	0.017
C/T	22	0.17	14	0.07	0.37 (0.18–0.75)	0.006	0.29 (0.10–0.80)	0.017
T/T	0	0.00	0	0.00	–	–	–	–
C	235	0.91	382	0.96	2.85 (1.41–5.78)	0.004	3.85 (1.42–10.45)	0.008
T	23	0.09	14	0.04	0.35 (0.17–0.71)	0.004	0.26 (0.09–0.70)	0.008
c.1196A>G								
<i>XRCCI</i>								
women								
A/A	50	0.22	20	0.23	1.05 (0.58–1.90)	0.860	1.14 (0.52–2.49)	0.747
A/G	137	0.61	62	0.72	1.64 (0.95–2.82)	0.074	2.12 (1.03–4.36)	0.042
G/G	37	0.17	4	0.05	0.25 (0.08–0.71)	0.010	0.13 (0.03–0.45)	0.002
A	237	0.53	102	0.59	1.45 (0.94–2.22)	0.089	1.87 (1.05–3.35)	0.035
G	211	0.47	70	0.41	0.69 (0.45–1.06)	0.089	0.53 (0.30–0.96)	0.035
men								
A/A	22	0.17	43	0.22	1.35 (0.76–2.38)	0.303	2.44 (1.08–5.37)	0.031
A/G	81	0.63	141	0.71	1.47 (0.91–2.35)	0.112	1.56 (0.82–2.97)	0.177
G/G	26	0.20	14	0.07	0.30 (0.15–0.60)	<0.001	0.13 (0.05–0.33)	<0.001

Table S10. *Cont.*

Polymorphism	Controls		KC		Crude OR		Adjusted OR ^a	
Genotype/Allele	Number	Frequency	Number	Frequency	(95% CI)	<i>p</i>	(95% CI)	<i>p</i>
c.1196A>G								
<i>XRCC1</i>								
men								
A	125	0.48	227	0.57	1.78 (1.18–2.69)	0.006	3.23 (0.82–5.72)	<0.001
G	133	0.52	169	0.43	0.31 (0.17–0.55)	<0.001	0.31 (0.17–0.55)	<0.001

p values <0.05 along with corresponding ORs are in bold; ^a OR adjusted for sex, age, co-occurrence of visual impairment, allergies, and family history for KC.